60 Degrees Pharmaceuticals Inc Revenue Growth Rates (SXTP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
60 Degrees Pharmaceuticals Inc   (NASDAQ: SXTP)
 

SXTP's Revenue Growth by Quarter and Year

60 Degrees Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SXTP Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.21
1st Quarter March 0.16
FY 0.37





SXTP Revenue second quarter 2026 Y/Y Growth Comment
60 Degrees Pharmaceuticals Inc reported Revenue surge of 107.9% year on year in the second quarter 2026, to $ 0.21 millions, this is lower than 60 Degrees Pharmaceuticals Inc 's recent average Revenue surge of 237.41%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Revenue growth. While 60 Degrees Pharmaceuticals Inc ' s Revenue doubling of 107.9% ranks overall at the positon no. 230 in the second quarter 2026.


SXTP Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 25 % 380 % -70.59 %
3rd Quarter September - 266.67 % 100 % 20 %
2nd Quarter June 107.9 % -9.09 % 450 % -
1st Quarter March 0 % 23.08 % 1200 % -
FY   - 66.67 % 328.57 % -

Financial Statements
60 Degrees Pharmaceuticals Inc 's second quarter 2026 Revenue $ 0.21 millions SXTP's Income Statement
60 Degrees Pharmaceuticals Inc 's second quarter 2025 Revenue $ 0.10 millions Quarterly SXTP's Income Statement


SXTP Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -31.82 % 100 % -16.67 %
3rd Quarter September - 340 % 9.09 % 200 %
2nd Quarter June 29.94 % -37.5 % -15.38 % 100 %
1st Quarter March -46.67 % -33.33 % 160 % -94.12 %
FY (Year on Year)   - 66.67 % 328.57 % -


Back to SXTP Growth rate Comparisons >> Back to SXTP Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #65
Overall #230

Revenue Y/Y Growth Statistics
High Average Low
1182.65 % 237.41 % -69.56 %
(Mar 31 2025)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #37
Healthcare Sector #65
Overall #230
Revenue Y/Y Growth Statistics
High Average Low
1182.65 % 237.41 % -69.56 %
(Mar 31 2025)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

60 Degrees Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
386.17 % 73.34 % -94.17 %
(Sep 30 2024)  


SXTP's II. Quarter Q/Q Revenue Comment
60 Degrees Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 29.94% quarter on quarter, to $ 0.21 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -37.5% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Revenue quarter on quarter growth. While 60 Degrees Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 364.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #81
Overall #364
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #40
Healthcare Sector #81
Overall #364
Revenue Q/Q Growth Statistics
High Average Low
386.17 % 73.34 % -94.17 %
(Sep 30 2024)  


SXTP's II. Quarter Q/Q Revenue Comment
60 Degrees Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 29.94% quarter on quarter, to $ 0.21 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -37.5% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Revenue quarter on quarter growth. While 60 Degrees Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 364.


60 Degrees Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1.11 $ 1.00 $ 1.01 $ 0.94 $ 0.63
Y / Y Revenue Growth (TTM) 76.05 % 57.89 % 68.15 % 131.54 % 84.45 %
Year on Year Revenue Growth Overall Ranking # 171 # 92 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 10.66 % -0.15 % 6.55 % 49.54 % -0.75 %
Seq. Revenue Growth (TTM) Overall Ranking # 2697 # 1783 # 0 # 0 # 0


Cumulative Revenue growth Comment
Although 60 Degrees Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 94.8% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 76.05% year on year, from 57.89% in Mar 31 2026.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 92 to 171.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 54
Overall # 171

Revenue TTM Y/Y Growth Statistics
High Average Low
150.71 %
 94.8 %
57.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 384
S&P 500 # 2697
Cumulative Revenue growth Comment
Although 60 Degrees Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 94.8% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 76.05% year on year, from 57.89% in Mar 31 2026.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 92 to 171.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 54
Overall # 171

Revenue TTM Y/Y Growth Statistics
High Average Low
150.71 %
94.8 %
57.89 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 384
S&P 500 # 2697




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SXTP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions


About 60 Degrees Pharmaceuticals Inc Revenue Growth Rates (SXTP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: 60 Degrees Pharmaceuticals Inc (CIK 1946563).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001554855-26-001860
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: 60 Degrees Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.